{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T23:26:03Z","timestamp":1781997963249,"version":"3.54.5"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Institute for Clinical and Experimental Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease characterized by chronic inflammation and progressive fibrosis of the biliary tree, leading to significant liver function impairment over time. There is a strong association with inflammatory bowel diseases (IBD), together representing a distinct and complex medical condition. Patients with PSC-IBD face a heightened risk of various cancers, particularly colorectal carcinoma (CRC) and cholangiocarcinoma (CCA) as the most common types. In this review, we aim to characterize the distinctive features of PSC-IBD-associated carcinomas. Cancer pathogenesis in PSC-IBD is shaped by various factors including dysregulated bile acid metabolism, gut dysbiosis, and unique immune responses. PSC-IBD-associated CRC is often right-sided and warrants vigilant monitoring due to its higher incidence and unique morphological features compared to CRC arising in the terrain of IBD alone. CCA shares substantial genetic similarities with extrahepatic CCA and poses diagnostic challenges since it is frequently detected at advanced stages due to symptom overlap with PSC. Besides, reliable predictive biomarkers for targeted therapy remain largely unexplored. The distinct molecular, genetic, and histopathological profiles of CRC and CCA in PSC-IBD underscore the complexity of these malignancies and highlight the need for continued research to develop precise therapeutic strategies.<\/jats:p>","DOI":"10.1007\/s00428-025-04072-y","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T21:36:21Z","timestamp":1742333781000},"page":"651-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unique clinical, morphological, and molecular characteristics of tumors associated with PSC-IBD"],"prefix":"10.1007","volume":"486","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-8664","authenticated-orcid":false,"given":"Andrea","family":"Vajsova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Cahova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Bajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Sticova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Juskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojmir","family":"Hlavaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"4072_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M (2017) Primary sclerosing cholangitis - a comprehensive review. J Hepatol 67:1298\u20131323","journal-title":"J Hepatol"},{"key":"4072_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","volume":"51","author":"R Chapman","year":"2010","unstructured":"Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010) Diagnosis and management of primary sclerosing cholangitis. Hepatology 51:660\u2013678","journal-title":"Hepatology"},{"key":"4072_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00534-010-0319-8","volume":"18","author":"H Sano","year":"2011","unstructured":"Sano H, Nakazawa T, Ando T et al (2011) Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 18:154\u2013161","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"4072_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/gut.51.5.731","volume":"51","author":"E Bj\u00f6rnsson","year":"2002","unstructured":"Bj\u00f6rnsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, Schrumpf E, Chapman RW (2002) Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 51:731","journal-title":"Gut"},{"key":"4072_CR5","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1007\/s10620-013-2697-7","volume":"58","author":"DF Schaeffer","year":"2013","unstructured":"Schaeffer DF, Win LL, Hafezi-Bakhtiari S, Cino M, Hirschfield GM, El-Zimaity H (2013) The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig Dis Sci 58:2608\u20132614","journal-title":"Dig Dis Sci"},{"key":"4072_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/gut.2004.046615","volume":"54","author":"EV Loftus","year":"2005","unstructured":"Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ (2005) PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54:91\u201396","journal-title":"Gut"},{"key":"4072_CR7","first-page":"124","volume":"32","author":"A Mertz","year":"2019","unstructured":"Mertz A, Nguyen NA, Katsanos KH, Kwok RM (2019) Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol 32:124","journal-title":"Ann Gastroenterol"},{"key":"4072_CR8","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s12072-021-10214-6","volume":"15","author":"A Lundberg B\u00e5ve","year":"2021","unstructured":"Lundberg B\u00e5ve A, Bergquist A, Bottai M, Warnqvist A, von Seth E, Nordenvall C (2021) Increased risk of cancer in patients with primary sclerosing cholangitis. Hepatol Int 15:1174\u20131182","journal-title":"Hepatol Int"},{"key":"4072_CR9","doi-asserted-by":"publisher","first-page":"16389","DOI":"10.3748\/wjg.v20.i44.16389","volume":"20","author":"M Yashiro","year":"2014","unstructured":"Yashiro M (2014) Ulcerative colitis-associated colorectal cancer. World J Gastroenterol: WJG 20:16389","journal-title":"World J Gastroenterol: WJG"},{"key":"4072_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1053\/j.gastro.2021.05.063","volume":"161","author":"SK Murthy","year":"2021","unstructured":"Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS (2021) AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology 161:1043\u20131051.e4","journal-title":"Gastroenterology"},{"key":"4072_CR11","doi-asserted-by":"publisher","unstructured":"Catanzaro E, Gringeri E, Burra P, Gambato M, (2023) Primary sclerosing cholangitis-associated cholangiocarcinoma: from pathogenesis to diagnostic and surveillance strategies. Cancers 15:4947.\u00a0https:\/\/doi.org\/10.3390\/cancers15204947","DOI":"10.3390\/cancers15204947"},{"key":"4072_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","volume":"28","author":"HH Zheng","year":"2016","unstructured":"Zheng HH, Jiang XL (2016) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol 28:383\u2013390","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4072_CR13","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/ecco-jcc\/jjac090","volume":"16","author":"R Zhang","year":"2022","unstructured":"Zhang R, Lauwers GY, Choi WT (2022) Increased risk of non-conventional and invisible dysplasias in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis 16:1825\u20131834","journal-title":"J Crohns Colitis"},{"key":"4072_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","volume":"126","author":"M Rutter","year":"2004","unstructured":"Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:451\u2013459","journal-title":"Gastroenterology"},{"key":"4072_CR15","doi-asserted-by":"publisher","DOI":"10.1152\/AJPGI.00079.2004","author":"SH Itzkowitz","year":"2004","unstructured":"Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation Am J Physiol Gastrointest Liver Physiol. https:\/\/doi.org\/10.1152\/AJPGI.00079.2004","journal-title":"Colorectal cancer in inflammatory bowel disease: the role of inflammation Am J Physiol Gastrointest Liver Physiol"},{"key":"4072_CR16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1158\/1541-7786.MCR-17-0451","volume":"16","author":"A Frick","year":"2018","unstructured":"Frick A, Khare V, Paul G, Lang M, Ferk F, Knasm\u00fcller S, Beer A, Oberhuber G, Gasche C (2018) Overt increase of oxidative stress and DNA damage in murine and human colitis and colitis-associated neoplasia. Mol Cancer Res 16:634\u2013642","journal-title":"Mol Cancer Res"},{"key":"4072_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/0-387-26283-0_3","volume":"130","author":"AJ Schottelius","year":"2006","unstructured":"Schottelius AJ, Dinter H (2006) Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 130:67\u201387","journal-title":"Cancer Treat Res"},{"key":"4072_CR18","doi-asserted-by":"publisher","unstructured":"Shaw DG, Aguirre-Gamboa R, Vieira MC, et al (2023) Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med 29(6):1520\u20131529.\u00a0https:\/\/doi.org\/10.1038\/s41591-023-02372-x","DOI":"10.1038\/s41591-023-02372-x"},{"key":"4072_CR19","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/ibd\/izad137","volume":"30","author":"A Wittek","year":"2024","unstructured":"Wittek A, Steglich B, Casar C et al (2024) A gradient of intestinal inflammation in primary sclerosing cholangitis. Inflamm Bowel Dis 30:900\u2013910","journal-title":"Inflamm Bowel Dis"},{"key":"4072_CR20","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1172\/JCI72334","volume":"124","author":"CL Sears","year":"2014","unstructured":"Sears CL, Geis AL, Housseau F (2014) Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest 124:4166\u20134172","journal-title":"J Clin Invest"},{"key":"4072_CR21","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1136\/gutjnl-2013-305257","volume":"63","author":"A Cougnoux","year":"2014","unstructured":"Cougnoux A, Dalmasso G, Martinez R et al (2014) Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 63:1932\u20131942","journal-title":"Gut"},{"key":"4072_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","volume":"66","author":"M Kummen","year":"2017","unstructured":"Kummen M, Holm K, Anmarkrud JA et al (2017) The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66:611\u2013619","journal-title":"Gut"},{"key":"4072_CR23","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1016\/j.cell.2022.09.015","volume":"185","author":"AB Dohlman","year":"2022","unstructured":"Dohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, Iliev ID (2022) A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell 185:3807\u20133822.e12","journal-title":"Cell"},{"key":"4072_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.12998\/wjcc.v6.i13.577","volume":"6","author":"TT Nguyen","year":"2018","unstructured":"Nguyen TT, Ung TT, Kim NH, Do JY (2018) Role of bile acids in colon carcinogenesis. World J Clin Cases 6:577","journal-title":"World J Clin Cases"},{"key":"4072_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/ibd.20886","volume":"15","author":"MMH Claessen","year":"2009","unstructured":"Claessen MMH, Lutgens MWMD, Van Buuren HR et al (2009) More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 15:1331\u20131336","journal-title":"Inflamm Bowel Dis"},{"key":"4072_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cgh.2017.07.023","volume":"16","author":"N Krugliak Cleveland","year":"2018","unstructured":"Krugliak Cleveland N, Rubin DT, Hart J et al (2018) Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol 16:68","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4072_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/1751-2980.12558","volume":"18","author":"YN Wang","year":"2017","unstructured":"Wang YN, Li J, Zheng WY et al (2017) Clinical characteristics of ulcerative colitis-related colorectal cancer in Chinese patients. J Dig Dis 18:684\u2013690","journal-title":"J Dig Dis"},{"key":"4072_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.crohns.2013.02.009","volume":"7","author":"U Navaneethan","year":"2013","unstructured":"Navaneethan U, Kochhar G, Venkatesh PGK, Bennett AE, Rizk M, Shen B, Kiran RP (2013) Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis 7:974\u2013981","journal-title":"J Crohns Colitis"},{"key":"4072_CR29","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/ecco-jcc\/jjad010","volume":"17","author":"S Grimsdottir","year":"2023","unstructured":"Grimsdottir S, Attauabi M, Kristine Dahl E, Burisch J, Seidelin JB (2023) Systematic review with meta-analysis: the impact of cancer treatments on the disease activity of inflammatory bowel diseases. J Crohns Colitis 17:1139\u20131153","journal-title":"J Crohns Colitis"},{"key":"4072_CR30","doi-asserted-by":"publisher","first-page":"E319","DOI":"10.1097\/SLA.0000000000005339","volume":"276","author":"C Lu","year":"2022","unstructured":"Lu C, Schardey J, Zhang T, Crispin A, Wirth U, Karcz KW, Bazhin AV, Andrassy J, Werner J, K\u00fchn F (2022) Survival outcomes and clinicopathological features in inflammatory bowel disease-associated colorectal cancer: a systematic review and meta-analysis. Ann Surg 276:E319\u2013E330","journal-title":"Ann Surg"},{"key":"4072_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41379-019-0419-1","volume":"33","author":"WT Choi","year":"2020","unstructured":"Choi WT, Yozu M, Miller GC, Shih AR, Kumarasinghe P, Misdraji J, Harpaz N, Lauwers GY (2020) Nonconventional dysplasia in patients with inflammatory bowel disease and colorectal carcinoma: a multicenter clinicopathologic study. Mod Pathol 33:933\u2013943","journal-title":"Mod Pathol"},{"key":"4072_CR32","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.prp.2019.01.010","volume":"215","author":"K Kamar\u00e1dov\u00e1","year":"2019","unstructured":"Kamar\u00e1dov\u00e1 K, Vo\u0161mikov\u00e1 H, Rozko\u0161ov\u00e1 K, Ry\u0161ka A, Tachec\u00ed I, Laco J (2019) Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions \u2013 single institution experience. Pathol Res Pract 215:730\u2013737","journal-title":"Pathol Res Pract"},{"key":"4072_CR33","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/PAS.0b013e318253645a","volume":"36","author":"X Liu","year":"2012","unstructured":"Liu X, Goldblum JR, Zhao Z, Landau M, Heald B, Pai R, Lin J (2012) Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma. Am J Surg Pathol 36:1228\u20131233","journal-title":"Am J Surg Pathol"},{"key":"4072_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"DM Muzny","year":"2012","unstructured":"Muzny DM, Bainbridge MN, Chang K et al (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330\u2013337","journal-title":"Nature"},{"key":"4072_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/his.14913","volume":"83","author":"R Zhang","year":"2023","unstructured":"Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT (2023) DNA content abnormality frequently develops in the right\/proximal colon in patients with primary sclerosing cholangitis and inflammatory bowel disease and is highly predictive of subsequent detection of dysplasia. Histopathology 83:116\u2013125","journal-title":"Histopathology"},{"key":"4072_CR36","unstructured":"Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease | Cancer Research | American Association for Cancer Research. https:\/\/aacrjournals.org\/cancerres\/article\/60\/13\/3333\/506396\/Increased-p53-Mutation-Load-in-Noncancerous-Colon. Accessed 15 Sep 2024"},{"key":"4072_CR37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0016-5085(94)90161-9","volume":"107","author":"TA Brentnall","year":"1994","unstructured":"Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, Burmer GC (1994) Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107:369\u2013378","journal-title":"Gastroenterology"},{"key":"4072_CR38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/humu.1380020602","volume":"2","author":"H Nagase","year":"1993","unstructured":"Nagase H, Nakamura Y (1993) Mutations of the APC adenomatous polyposis coli) gene. Hum Mutat 2:425\u2013434","journal-title":"Hum Mutat"},{"key":"4072_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cell.2020.06.036","volume":"182","author":"S Olafsson","year":"2020","unstructured":"Olafsson S, McIntyre RE, Coorens T et al (2020) Somatic evolution in non-neoplastic IBD-affected colon. Cell 182:672\u2013684.e11","journal-title":"Cell"},{"key":"4072_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41467-022-35592-9","volume":"14","author":"WK Chatila","year":"2023","unstructured":"Chatila WK, Walch H, Hechtman JF et al (2023) Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. Nat Commun 14:110","journal-title":"Nat Commun"},{"key":"4072_CR41","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/ibd\/izac087","volume":"28","author":"M De Krijger","year":"2022","unstructured":"De Krijger M, Carvalho B, Rausch C et al (2022) genetic profiling of colorectal carcinomas of patients with primary sclerosing cholangitis and inflammatory bowel disease. Inflamm Bowel Dis 28:1309\u20131320","journal-title":"Inflamm Bowel Dis"},{"key":"4072_CR42","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3748\/wjg.v19.i14.2234","volume":"19","author":"P Wohl","year":"2013","unstructured":"Wohl P, Hucl T, Drastich P et al (2013) Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis. World J Gastroenterol 19:2234\u20132241","journal-title":"World J Gastroenterol"},{"key":"4072_CR43","doi-asserted-by":"crossref","unstructured":"Sepulveda AR, Hamilton SR, Allegra CJ, et al (2017) Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. 101200\/JOP2017022152 13:333\u2013337","DOI":"10.1200\/JOP.2017.022152"},{"key":"4072_CR44","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1172\/JCI62888","volume":"122","author":"PE Dub\u00e9","year":"2012","unstructured":"Dub\u00e9 PE, Yan F, Punit S, Girish N, McElroy SJ, Washington MK, Polk DB (2012) Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J Clin Invest 122:2780","journal-title":"J Clin Invest"},{"key":"4072_CR45","doi-asserted-by":"publisher","first-page":"22257","DOI":"10.18632\/oncotarget.8076","volume":"7","author":"HC Hsu","year":"2016","unstructured":"Hsu HC, Thiam TK, Lu YJ et al (2016) Mutations of KRAS\/NRAS\/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget 7:22257","journal-title":"Oncotarget"},{"key":"4072_CR46","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520","journal-title":"N Engl J Med"},{"key":"4072_CR47","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1038\/s41598-020-60255-4","volume":"10","author":"GE Idos","year":"2020","unstructured":"Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C (2020) The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep 10:3360","journal-title":"Sci Rep"},{"key":"4072_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/path.1895","volume":"208","author":"JM Michael-Robinson","year":"2006","unstructured":"Michael-Robinson JM, Pandeya N, Walsh MD, Biemer-Huttmann AE, Eri RD, Buttenshaw RL, Lincoln D, Clouston AD, Jaas JR, Radford-Smith GL (2006) Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer. J Pathol 208:381\u2013387","journal-title":"J Pathol"},{"key":"4072_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/PAS.0b013e3181bc96f9","volume":"34","author":"JT Lewis","year":"2010","unstructured":"Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC (2010) Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 34:27\u201334","journal-title":"Am J Surg Pathol"},{"key":"4072_CR50","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.bbadis.2017.08.020","volume":"1864","author":"BK Chung","year":"2018","unstructured":"Chung BK, Karlsen TH, Folseraas T (2018) Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864:1390\u20131400","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"4072_CR51","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"O Chazouilleres","year":"2022","unstructured":"Chazouilleres O, Beuers U, Bergquist A, Karlsen TH, Levy C, Samyn M, Schramm C, Trauner M (2022) EASL clinical practice guidelines on sclerosing cholangitis. J Hepatol 77:761\u2013806","journal-title":"J Hepatol"},{"key":"4072_CR52","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3892\/ijo.2013.2038","volume":"43","author":"Y Ishii","year":"2013","unstructured":"Ishii Y, Sasaki T, Serikawa M et al (2013) Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: \u03b9mplications for cholangiocarcinogenesis. Int J Oncol 43:1073\u20131079","journal-title":"Int J Oncol"},{"key":"4072_CR53","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/ijc.34350","volume":"152","author":"R Lieshout","year":"2023","unstructured":"Lieshout R, Kamp EJCA, Verstegen MMA et al (2023) Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: a role for IL-17A. Int J Cancer 152:2607\u20132614","journal-title":"Int J Cancer"},{"key":"4072_CR54","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0140-6736(02)07374-9","volume":"359","author":"AJ Grant","year":"2002","unstructured":"Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH (2002) Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359:150\u2013157","journal-title":"Lancet"},{"key":"4072_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTAUTO.2020.100054","author":"M de Krijger","year":"2020","unstructured":"de Krijger M, Visseren T, Wildenberg ME, Hooijer GKJ, Verstegen MMA, van der Laan LJW, de Jonge WJ, Verheij J, Ponsioen CY (2020) Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease. J Transl Autoimmun. https:\/\/doi.org\/10.1016\/J.JTAUTO.2020.100054","journal-title":"J Transl Autoimmun"},{"key":"4072_CR56","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.32193","volume":"75","author":"JJ Graham","year":"2021","unstructured":"Graham JJ, Mukherjee S, Yuksel M et al (2021) Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis. Hepatology 75:518\u2013530","journal-title":"Hepatology"},{"key":"4072_CR57","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.4254\/wjh.v8.i32.1354","volume":"8","author":"S Kiziltas","year":"2016","unstructured":"Kiziltas S (2016) Toll-like receptors in pathophysiology of liver diseases. World J Hepatol 8:1354","journal-title":"World J Hepatol"},{"key":"4072_CR58","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/ajg.2016.55","volume":"111","author":"AF Gulamhusein","year":"2016","unstructured":"Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN (2016) Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol 111:705","journal-title":"Am J Gastroenterol"},{"key":"4072_CR59","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","volume":"23","author":"L Bajer","year":"2017","unstructured":"Bajer L, Kverka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, Brezina J, Wohl P, Spicak J, Drastich P (2017) Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol 23:4548\u20134558","journal-title":"World J Gastroenterol"},{"key":"4072_CR60","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1136\/gutjnl-2019-320008","volume":"69","author":"MC R\u00fchlemann","year":"2020","unstructured":"R\u00fchlemann MC, Solovjeva MEL, Zenouzi R, Liwinski T, Kummen M, Lieb W, Hov JR, Schramm C, Franke A, Bang C (2020) Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut 69:1890\u20131892","journal-title":"Gut"},{"key":"4072_CR61","unstructured":"Rawla P, Samant H (2023) Primary sclerosing cholangitis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537181\/"},{"key":"4072_CR62","doi-asserted-by":"crossref","unstructured":"Trilianos P, Agnihotri A, Ucbilek E, Gurakar A (2016) Greater biosynthetic liver dysfunction in primary sclerosing cholangitis suggests co-existent or impending cholangiocarcinoma. http:\/\/www.xiahepublishing.com\/ 4:1\u20134","DOI":"10.14218\/JCTH.2015.00048"},{"key":"4072_CR63","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1572-0241.2004.04106.x","volume":"99","author":"E Bj\u00f6rnsson","year":"2004","unstructured":"Bj\u00f6rnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R (2004) Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 99:502\u2013508","journal-title":"Am J Gastroenterol"},{"key":"4072_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/cld.902","volume":"15","author":"E Gochanour","year":"2020","unstructured":"Gochanour E, Jayasekera C, Kowdley K (2020) Primary sclerosing cholangitis: epidemiology, genetics, diagnosis, and current management. Clin Liver Dis (Hoboken) 15:125\u2013128","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"4072_CR65","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/jgh3.12405","volume":"4","author":"D Chahal","year":"2020","unstructured":"Chahal D, Shamatutu C, Salh B, Davies J (2020) The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival. JGH Open 4:1128","journal-title":"JGH Open"},{"key":"4072_CR66","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s10620-006-9681-4","volume":"52","author":"J Fevery","year":"2007","unstructured":"Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W (2007) Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 52:3123\u20133135","journal-title":"Dig Dis Sci"},{"key":"4072_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bpg.2015.02.006","volume":"29","author":"Y Nakanuma","year":"2015","unstructured":"Nakanuma Y, Kakuda Y (2015) Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol 29:277\u2013293","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"4072_CR68","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/hep.30210","volume":"69","author":"G Carpino","year":"2019","unstructured":"Carpino G, Cardinale V, Folseraas T et al (2019) Neoplastic transformation of the peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis. Hepatology 69:622\u2013638","journal-title":"Hepatology"},{"key":"4072_CR69","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.31110","volume":"72","author":"B Goeppert","year":"2020","unstructured":"Goeppert B, Folseraas T, Roessler S et al (2020) genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities. Hepatology 72:1253\u20131266","journal-title":"Hepatology"},{"key":"4072_CR70","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003\u20131010","journal-title":"Nat Genet"},{"key":"4072_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0115383","author":"CR Churi","year":"2014","unstructured":"Churi CR, Shroff R, Wang Y et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0115383","journal-title":"PLoS ONE"},{"key":"4072_CR72","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/cas.13582","volume":"109","author":"T Shibata","year":"2018","unstructured":"Shibata T, Arai Y, Totoki Y (2018) Molecular genomic landscapes of hepatobiliary cancer. Cancer Sci 109:1282","journal-title":"Cancer Sci"},{"key":"4072_CR73","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH et al (2017) Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 7:1116\u20131135","journal-title":"Cancer Discov"},{"key":"4072_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000461","author":"MM Grimsrud","year":"2024","unstructured":"Grimsrud MM, Forster M, Goeppert B et al (2024) Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis. Hepatol Commun. https:\/\/doi.org\/10.1097\/HC9.0000000000000461","journal-title":"Hepatol Commun"},{"key":"4072_CR75","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.3390\/cells11233929","volume":"11","author":"P Chmiel","year":"2022","unstructured":"Chmiel P, G\u0119ca K, Rawicz-Pruszy\u0144ski K, Polkowski WP, Sk\u00f3rzewska M (2022) FGFR inhibitors in cholangiocarcinoma\u2014a novel yet primary approach: where do we stand now and where to head next in targeting this axis? Cells 11:3929","journal-title":"Cells"},{"key":"4072_CR76","volume":"14","author":"V Sumbly","year":"2022","unstructured":"Sumbly V, Landry I, Rizzo V (2022) Ivosidenib for IDH1 mutant cholangiocarcinoma: a narrative review. Cureus 14","journal-title":"Cureus"},{"key":"4072_CR77","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/23808993.2021.1910023","volume":"6","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G (2021) Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives. Expert Rev Precis Med Drug Dev 6:225\u2013227","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"4072_CR78","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.21037\/jgo.2019.08.08","volume":"10","author":"K Mody","year":"2019","unstructured":"Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF (2019) Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol 10:1099","journal-title":"J Gastrointest Oncol"},{"key":"4072_CR79","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS et al (2021) Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22:1290\u20131300","journal-title":"Lancet Oncol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04072-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04072-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04072-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:02:43Z","timestamp":1771999363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04072-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4072"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04072-y","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article involved no research with human participants or animals, as it is purely based on existing literature. Thus, no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of\u00a0Interest."}}]}}